Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2007

Martinez-Salamanca JI, Rao S, Ramanathan R, Gonzalez J, Mandhani A, Yang X, et al. Nerve advancement with end-to-end reconstruction after partial neurovascular bundle resection:a feasibility study. J Endourol. 2007;21(8):830-5.

Wang F, Wang L, Briggs C, Sicinska E, Gaston SM, Mamon H, et al. DNA degradation test predicts success in whole-genome amplification from diverse clinical samples. J Mol Diagn. 2007;9(4):441-51.

He B, Xu W, Santini PA, Polydorides AD, Chiu A, Estrella J, et al. Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity. 2007;26(6):812-26.

A Crowson N, Magro C, Mihm MC. Unusual histologic and clinical variants of melanoma: implications for therapy. Curr Oncol Rep. 2007;9(5):403-10.

Zapata M, Cohen C, Siddiqui MT. Immunohistochemical expression of SMAD4, CK19, and CA19-9 in fine needle aspiration samples of pancreatic adenocarcinoma: Utility and potential role. Cytojournal. 2007;4:13.

Bhalla R, Siddiqui MT, Mandich D, Cartun RW, Fiel-Gan MD, Nassar A, et al. Diagnostic utility of D2-40 and podoplanin in effusion cell blocks. Diagn Cytopathol. 2007;35(6):342-7.

Jaggi JS, Henke E, Seshan SV, Kappel BJ, Chattopadhyay D, May C, et al. Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization. PLoS One. 2007;2(3):e267.

Vang R, Gown AM, Farinola M, Barry TS, Wheeler DT, Yemelyanova A, et al. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am J Surg Pathol. 2007;31(5):653-63.

Rheault MN, van Burik J-, Mauer M, Ingulli E, Ferrieri P, Jessurun J, et al. Cat-scratch disease relapse in a kidney transplant recipient. Pediatr Transplant. 2007;11(1):105-9.

Heymann JJ, Benson MC, O'Toole KM, Malyszko B, Brody R, Vecchio D, et al. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer. J Clin Oncol. 2007;25(1):77-84.